help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 72, No. 2 455-461
doi:10.1210/jcem-72-2-455
Copyright © 1991 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KREMPF, M.
Right arrow Articles by CHATAL, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KREMPF, M.
Right arrow Articles by CHATAL, J. F.

Use of m-[131I]Iodobenzylguanidine in the Treatment of Malignant Pheochromocytoma

M. KREMPF, J. LUMBROSO, R. MORNEX, A. J. BRENDEL, J. L. WEMEAU, M. J. DELISLE, B. AUBERT, P. CARPENTIER, M. C. FLEURY-GOYON, C. GIBOLD, M. GUYOT, B. LAHNECHE, X. MARCHANDISE, M. SCHLUMBERGER, B. CHARBONNEL and J. F. CHATAL

University Hospital (MX., B.C., J.F.C.) 44035 Nantes, France
Institut Gustaue-Roussy (J.L., B.A., M.S.) 94805 Villejuif, France
University Hospital (R.M., M.C.F.-G., B.L.) 69437 Lyon, France
University Hospital (A.J.B., M.G.) 33076 Bordeaux, France
Centre Oscar Lambret and University Hospital (J.L. W., P.C., X.M.) 59003 Lille, France
Institut Jean Godinot (M.J.D., C.G.) 51056 Reims, France

Address all correspondence and requests for reprints to: Dr. Michel Krempf, Clinique Endocrinologique, Place Alexis Ricordeau, Hôtel Dieu, 44035 Nantes Cedex, France.

The efficacy and safety of m-[131I]iodobenzylguanidine ([131I]MIBG) were assessed in 15 patients with malignant pheochromocytomas in a nonrandomized, single arm trial, in which patients were treated with [131I]MIBG (SA, 740 megabequerel/mg) every 3 months. Seven of these patients had bone and soft tissue metastases, 4 had only soft metastases, and 4 had only bone metastases. The follow-up period ranged from 6–54 months; the number of doses ranged from 2–11, with 2.9 (78.4 mCi) to 9.25 gigabequerel (GBq) (250 mCi)/administration and a cumulative activity from 11.1–85.90 GBq (300–2322 mCi). The absorbed cumulative dose in tumors ranged from 12–155 Gy. A beneficial effect of the treatment was observed in 9 patients (60%). No complete remission of the disease was observed. Seven patients died during the study, among whom 4 never responded to the treatment. Seven had hormonal responses (4 complete and 3 partial), with a duration ranging from 5–48 months. Among these patients, 4 relapsed, and 3 died within 3 months. Five patients had partial tumoral responses mainly located in soft tissues and for a duration ranging from 29–54 months. All patients with a hormonal response had objective improvement in clinical status and blood pressure. There was no clear-cut relationship between the cumulative dose and the responses. The main side-effect observed in 1 patient with widespread bone metastases after three doses (12.9 GBq) was a pancytopenia, which resolved after treatment was discontinued. This study suggests that repeated [131I]MIBG treatment could be effective in patients with advanced malignant pheochromocytoma.

Received January 2, 1990.




This article has been cited by other articles:


Home page
RadioGraphicsHome page
C. M. Intenzo, S. Jabbour, H. C. Lin, J. L. Miller, S. M. Kim, D. M. Capuzzi, and E. P. Mitchell
Scintigraphic Imaging of Body Neuroendocrine Tumors
RadioGraphics, September 1, 2007; 27(5): 1355 - 1369.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert
Current Treatment of Malignant Pheochromocytoma
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
G. Eisenhofer, S. R Bornstein, F. M Brouwers, N.-K. V Cheung, P. L Dahia, R. R de Krijger, T. J Giordano, L. A Greene, D. S Goldstein, H. Lehnert, et al.
Malignant pheochromocytoma: current status and initiatives for future progress
Endocr. Relat. Cancer, September 1, 2004; 11(3): 423 - 436.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. A. Kaltsas, G. M. Besser, and A. B. Grossman
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
Endocr. Rev., June 1, 2004; 25(3): 458 - 511.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society